Figure 3

CEACAM1-1 splicing isoforms in patients with lung cancer. (a) CEACAM1-1 splicing isoforms. The location of the primers used in the study is also indicated. (b) PCR amplifications of different CEACAM1 splice forms in 11 normal lung tissues and paired tumors from patients included in the splice array. CEACAM1-1 was amplified with primers 01/08; the L- or S-forms in CEACAM1-1 were evaluated with primers 06/09; and CEACAM1-3 was determined with primers 01/15. IPO8 expression served as the control. Additional PCRs were done but are not shown in the figure: CEACAM1-3A was detected with primers 01/14, and L- and S- forms of CEACAM1-3 and CEACAM1-3A were discriminated using primers 20/09 and 18/09, respectively. (c) CEACAM1-3A was evaluated by real-time PCR using primers 16-17 in 23 primary NSCLC tumors and their corresponding normal lung samples. ** p < 0.01.